90 related articles for article (PubMed ID: 23167798)
1. Biological evaluation of 3-acyl-2-arylamino-1,4-naphthoquinones as inhibitors of Hsp90 chaperoning function.
Ríos D; Benites J; Valderrama JA; Farias M; Pedrosa RC; Verrax J; Buc Calderon P
Curr Top Med Chem; 2012; 12(19):2094-102. PubMed ID: 23167798
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death.
Beck R; Verrax J; Gonze T; Zappone M; Pedrosa RC; Taper H; Feron O; Calderon PB
Biochem Pharmacol; 2009 Feb; 77(3):375-83. PubMed ID: 19014912
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
4. Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.
Bargiotti A; Musso L; Dallavalle S; Merlini L; Gallo G; Ciacci A; Giannini G; Cabri W; Penco S; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Barbarino M; Pisano C; Giommarelli C; Zuco V; De Cesare M; Zunino F
Eur J Med Chem; 2012 Jul; 53():64-75. PubMed ID: 22538015
[TBL] [Abstract][Full Text] [Related]
5. Molecular chaperone Hsp90 as a target for oxidant-based anticancer therapies.
Beck R; Dejeans N; Glorieux C; Pedrosa RC; Vásquez D; Valderrama JA; Calderon PB; Verrax J
Curr Med Chem; 2011; 18(18):2816-25. PubMed ID: 21568884
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold.
Hadden MK; Hill SA; Davenport J; Matts RL; Blagg BS
Bioorg Med Chem; 2009 Jan; 17(2):634-40. PubMed ID: 19101151
[TBL] [Abstract][Full Text] [Related]
7. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Miyata Y
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 is cleaved by reactive oxygen species at a highly conserved N-terminal amino acid motif.
Beck R; Dejeans N; Glorieux C; Creton M; Delaive E; Dieu M; Raes M; Levêque P; Gallez B; Depuydt M; Collet JF; Calderon PB; Verrax J
PLoS One; 2012; 7(7):e40795. PubMed ID: 22848402
[TBL] [Abstract][Full Text] [Related]
9. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
Koay YC; Wahyudi H; McAlpine SR
Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis.
Koca İ; Özgür A; Er M; Gümüş M; Açikalin Coşkun K; Tutar Y
Eur J Med Chem; 2016 Oct; 122():280-290. PubMed ID: 27376491
[TBL] [Abstract][Full Text] [Related]
11. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways.
Wang R; Shao F; Liu Z; Zhang J; Wang S; Liu J; Liu H; Chen H; Liu K; Xia M; Wang Y
Chem Biol Interact; 2013 Sep; 205(1):1-10. PubMed ID: 23777986
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study.
Verrax J; Delvaux M; Beghein N; Taper H; Gallez B; Buc Calderon P
Free Radic Res; 2005 Jun; 39(6):649-57. PubMed ID: 16036343
[TBL] [Abstract][Full Text] [Related]
13. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
14. 4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
Baruchello R; Simoni D; Marchetti P; Rondanin R; Mangiola S; Costantini C; Meli M; Giannini G; Vesci L; Carollo V; Brunetti T; Battistuzzi G; Tolomeo M; Cabri W
Eur J Med Chem; 2014 Apr; 76():53-60. PubMed ID: 24565573
[TBL] [Abstract][Full Text] [Related]
15. The Hsp90 molecular chaperone: an open and shut case for treatment.
Pearl LH; Prodromou C; Workman P
Biochem J; 2008 Mar; 410(3):439-53. PubMed ID: 18290764
[TBL] [Abstract][Full Text] [Related]
16. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
[TBL] [Abstract][Full Text] [Related]
17. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
18. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
Hall JA; Seedarala S; Rice N; Kopel L; Halaweish F; Blagg BS
J Nat Prod; 2015 Apr; 78(4):873-9. PubMed ID: 25756299
[TBL] [Abstract][Full Text] [Related]
19. ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation.
Kimura H; Yukitake H; Tajima Y; Suzuki H; Chikatsu T; Morimoto S; Funabashi Y; Omae H; Ito T; Yoneda Y; Takizawa M
Chem Biol; 2010 Jan; 17(1):18-27. PubMed ID: 20142037
[TBL] [Abstract][Full Text] [Related]
20. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
